NT219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2 and STAT3. We are currently advancing NT219 as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) in a phase 1/2 study.
CM24 is a monoclonal antibody blocking CEACAM1, a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. The Company advances CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment of pancreatic cancer.
Purple Biotech has entered into a clinical collaboration agreement with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in addition to chemotherapy in patients with pancreatic cancer.
IM1240 is a conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong anti-tumoral immune response. The third arm of the compound binds to 5T4, a Tumor-Associated antigen (TAA) expressed in a variety of solid tumors and that correlates with advanced disease, increased invasiveness, and poor clinical outcomes. The compound is distinguished from other products targeting 5T4+ tumors both by its dual engagement of T cell and NK cells and by the cleavable capping technology. Currently, we are conducting the preclinical studies required for IND-filing.